Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 2 |
| HIV/AIDS Therapeutics Market to 2017 - Introduction | 10 | 1 |
| GBI Research Report Guidance | 10 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Global Overview | 11 | 4 |
| Disease Overview | 11 | 2 |
| Market Overview | 13 | 1 |
| Overview of Recent Research Advancements in HIV/AIDS Therapy | 14 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Market Characterization | 15 | 18 |
| Market Forecasts | 15 | 1 |
| Branded Versus Generics | 16 | 1 |
| Annual Cost of Therapy | 17 | 1 |
| Treatment Usage Patterns | 18 | 2 |
| Diseased Population | 20 | 2 |
| Treatment Seeking Population | 22 | 1 |
| Diagnosis Population | 23 | 2 |
| Prescription Population | 25 | 1 |
| Geographical Distribution | 26 | 2 |
| Drivers and Restraints | 28 | 1 |
| Market Drivers | 28 | 1 |
| Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations | 28 | 1 |
| Awareness in the US | 28 | 1 |
| Awareness in Europe | 28 | 1 |
| Awareness in Japan | 29 | 1 |
| New Product Launches will Increase Uptake and Drive the Market | 29 | 1 |
| Increase in Drug Prices will Drive Growth and Lessen the Impact of Generics | 30 | 1 |
| HIV/AIDS Therapy and Switch to New Drugs | 30 | 1 |
| Market Restraints | 30 | 1 |
| Patent Expiries and the Subsequent Entry of Generics will Negatively Impact the Market | 30 | 1 |
| Social Stigma Associated with HIV/AIDS Leads to Low Treatment Seeking Rate | 31 | 1 |
| Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes | 32 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - The US | 33 | 10 |
| Market Forecasts | 33 | 1 |
| Annual Cost of Therapy | 34 | 1 |
| Treatment Usage Patterns | 35 | 2 |
| Diseased Population | 37 | 1 |
| Treatment Seeking Population | 38 | 2 |
| Diagnosis Population | 40 | 1 |
| Prescription Population | 41 | 2 |
| HIV/AIDS Therapeutics Market to 2017 - Top Five European Countries | 43 | 11 |
| Market Forecasts | 43 | 2 |
| Revenue by Country | 45 | 1 |
| Annual Cost of Therapy | 46 | 1 |
| Treatment Usage Patterns | 47 | 2 |
| Diseased Population | 49 | 1 |
| Treatment Seeking Population | 50 | 1 |
| Diagnosis Population | 51 | 2 |
| Prescription Population | 53 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Japan | 54 | 10 |
| Market Forecasts | 54 | 1 |
| Annual Cost of Therapy | 55 | 2 |
| Treatment Usage Patterns | 57 | 1 |
| Diseased Population | 58 | 2 |
| Treatment Seeking Population | 60 | 1 |
| Diagnosis Population | 61 | 1 |
| Prescription Population | 62 | 2 |
| HIV/AIDS Therapeutics Market to 2017 - Pipeline Assessment | 64 | 10 |
| Major Classes of Drugs | 64 | 1 |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) | 64 | 1 |
| Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | 64 | 2 |
| Protease Inhibitors | 66 | 1 |
| Viral Fusion (or Entry) Inhibitors | 66 | 1 |
| HIV Integrase Strand Transfer Inhibitors | 66 | 1 |
| Multi-Class Combination Products | 66 | 1 |
| Pipeline Overview | 66 | 1 |
| Strategic Pipeline Assessment | 67 | 1 |
| HIV/AIDS Therapeutics Pipeline - Pipeline by Clinical Phases of Development | 67 | 1 |
| HIV/AIDS Therapeutics - Phase III Clinical Pipeline | 67 | 1 |
| HIV/AIDS Therapeutics - Phase II Clinical Pipeline | 68 | 1 |
| HIV/AIDS Therapeutics - Phase I Clinical Pipeline | 69 | 1 |
| HIV/AIDS Therapeutics - Preclinical Pipeline | 70 | 1 |
| HIV/AIDS Therapeutics - Discovery Clinical Pipeline | 71 | 1 |
| HIV/AIDS Therapeutics - Pipeline by Mechanism of Action | 72 | 1 |
| HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development | 73 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Competitive Landscape | 74 | 12 |
| Major Company Profiles | 75 | 1 |
| Gilead Sciences, Inc | 76 | 1 |
| SWOT Analysis | 76 | 1 |
| GlaxoSmithKline (GSK) | 77 | 1 |
| SWOT Analysis | 78 | 1 |
| Bristol-Myers Squibb (BMS) | 79 | 1 |
| SWOT Analysis | 80 | 1 |
| Abbott Laboratories | 81 | 1 |
| SWOT Analysis | 82 | 1 |
| Merck | 83 | 1 |
| SWOT Analysis | 84 | 1 |
| Pfizer | 85 | 1 |
| SWOT Analysis | 85 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Licencing and Partnership Deals | 86 | 6 |
| Overview: Deals by Type and Geography | 86 | 1 |
| Mergers and Acquisitions | 87 | 1 |
| Merger of GSK and Pfizer | 87 | 1 |
| Viral Genetics, Inc. Completed its Acquisition of V-Clip Pharmaceuticals | 88 | 1 |
| Licensing Agreements | 88 | 1 |
| Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs | 89 | 1 |
| Altor BioScience licenses T-cell receptors targeting HIV and hepatitis C from Massachusetts General Hospital | 89 | 1 |
| Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications | 89 | 1 |
| Microbicide Developer Receives License for Novel HIV Microbicide Candidate from Merck &Co., Inc. | 90 | 1 |
| Idenix Pharmaceuticals and GlaxoSmithKline have entered into a licensing agreement to co-develop IDX899 for the treatment of HIV infection | 90 | 1 |
| Myriad Pharmaceuticals, has entered into a Bevirimat acquisition agreement with Panacos Pharmaceuticals Inc | 90 | 1 |
| Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada(R) and TMC278 | 91 | 1 |
| GlaxoSmithKline agrees royalty-free licensing deal for HIV drug | 91 | 1 |
| Tibotec and Emcure Collaborate on Access to Darunavir for India | 91 | 1 |
| IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide | 91 | 1 |
| HIV/AIDS Therapeutics Market to 2017 - Appendix | 92 | 7 |
| Market Definitions | 92 | 1 |
| Abbreviations | 92 | 1 |
| Research Methodology | 93 | 2 |
| Coverage | 93 | 1 |
| Secondary Research | 93 | 1 |
| Primary Research | 94 | 1 |
| Therapeutic Landscape | 94 | 3 |
| Epidemiology-based Forecasting | 95 | 1 |
| Market Size by Geography | 96 | 1 |
| Geographical Landscape | 97 | 1 |
| Pipeline Analysis | 97 | 1 |
| Competitive Landscape | 97 | 1 |
| Expert Panel Validation | 97 | 1 |
| Contact Us | 97 | 1 |
| Disclaimer | 97 | 1 |
| Sources | 98 | 1 |